Wordt geladen...
AURA3 trial: does Tagrisso (osimertinib) have the potential to become the new standard of care for second-line treatment of patients with EGFR T790M mutation-positive locally advanced or metastatic NSCLC
Vassiliki A Papadimitrakopoulou speaks to Roshaine Wijayatunga, Managing Commissioning Editor: Dr Papadimitrakopoulou is the Jay and Lori Eisenberg Distinguished Professor of Medicine and Chief of the section of Thoracic Medical Oncology in the Department of Thoracic/Head and Neck Medical Oncology a...
Bewaard in:
| Gepubliceerd in: | Lung Cancer Manag |
|---|---|
| Hoofdauteur: | |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Future Medicine Ltd
2016
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6310333/ https://ncbi.nlm.nih.gov/pubmed/30643560 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/lmt-2017-0001 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|